Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?

Autor: De Keukeleire SJ; Department of Medical Oncology, Ghent University Hospital, Gent 9000, Belgium., Vermassen T; Drug Research Unit Ghent, Ghent University Hospital, Gent 9000, Belgium., Nezhad ZM; Drug Research Unit Ghent, Ghent University Hospital, Gent 9000, Belgium., Kerre T; Department of Hematology, Ghent University Hospital, Gent 9000, Belgium., Kruse V; Department of Lung Diseases-Thoracic Oncology, Gent University Hospital, Gent 9000, Belgium., Vlierberghe HV; Department of Medical Oncology, AZ Nikolaas, Sint-Niklaas 9100, Belgium., Vermaelen K; Department of Gastroenterology & Hepatology, Ghent University Hospital, Gent 9000, Belgium., Rottey S; Department of Medical Oncology, Ghent University Hospital, Gent 9000, Belgium.; Drug Research Unit Ghent, Ghent University Hospital, Gent 9000, Belgium.

Publikováno v: Immunotherapy [Immunotherapy] 2021 Apr; Vol. 13 (5), pp. 409-418. Date of Electronic Publication: 2021 Jan 25.